Abstract
GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.
Original language | English (US) |
---|---|
Pages (from-to) | 905-910 |
Number of pages | 6 |
Journal | International journal of oncology |
Volume | 6 |
Issue number | 4 |
State | Published - Jan 1 1995 |
Externally published | Yes |
Keywords
- Gonadotropin-releasing hormone (GnRH)
- Ovarian cancer
- Vascular endothelial growth factor (VEGF)
- Vascular permeability factor (VPF)
ASJC Scopus subject areas
- Oncology
- Cancer Research